Exosome Diagnostics, Inc., a developer of what it believes to be revolutionary, biofluid-based molecular diagnostics, announced that Tom McLain, CEO of Exosome Diagnostics, presented, on Tuesday, October 13, 2015, at the Fourth Annual OktoberINVESTfest event (http://www.oktoberinvestfest.com/) at the New York Academy of Sciences in New York City. Mr. McLain’s presentation at this very high-level conference focused on the evolving role of diagnostics in advancing personalized medicine and the progress that Exosome Diagnostics has made in this field. Exosome Diagnostics plans to launch, in 2015, a suite of innovative liquid biopsy tests based on its proprietary, exosome-based ExoLution™ platform to enhance mutation detection, screening, and drug-resistance monitoring for various types of cancer. Exosomes are sub-cellular vesicular messengers released by all living cells into biofluids, such as plasma/serum, urine, cerebrospinal fluid, and saliva. Exosomes can contain RNA, DNA, and proteins from their cell of origin. Exosome Diagnostics’ technology platform can achieve real-time access to comprehensive molecular information about cells in the body without direct access to the actual cells. The company is also exploring the development of exosome-based diagnostics for diseases beyond cancer, including neurodegenerative diseases. OktoberINVESTfest is hosted by Invest in Bavaria (http://www.invest-in-bavaria.com/en.html), the investment and location marketing organization of the German State of Bavaria’s Ministry for Economic Affairs, Media, Energy and Technology. The conference brings together US and German investors, innovators, industry leaders, and Bavarian state representatives, as well as a number of innovative North American and German small and microcap companies and also some early-stage investment opportunities.
Login Or Register To Read Full Story